Clinical Report: Blood-Based Biomarker Model for Postmenopausal EEC Risk Prediction
Overview
This study developed a clinical risk prediction model for postmenopausal endometrioid endometrial carcinoma (EEC) using preoperative blood biomarkers. The model demonstrated high sensitivity and specificity.
Background
Endometrial cancer (EC) is a significant health concern, particularly among postmenopausal women, who represent over 80% of cases. Current diagnostic methods have limitations, necessitating the exploration of blood-based biomarkers for risk assessment.
Data Highlights
Factor
Value
Area Under Curve (AUC)
0.936
Specificity
89.1%
Sensitivity
90.1%
Key Findings
Five independent risk factors for postmenopausal EEC were identified: BMI, CA125, HE4, PLR, and ALB.
The clinical prediction model showed an AUC of 0.936, indicating excellent predictive performance.
At the optimal Youden index, the model achieved a specificity of 89.1% and sensitivity of 90.1%.
The model was implemented in an online calculator for clinical use.
Current diagnostic modalities for EEC have limitations that blood biomarkers may help address.
Clinical Implications
The identification of specific blood biomarkers as risk factors for postmenopausal EEC may assist in risk stratification.
Conclusion
The study established a blood-based biomarker model for predicting postmenopausal EEC risk, demonstrating robust performance metrics.
